Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: posts positive lung cancer drug data

( - A Phase III study showed that Roche's Tecentriq and Avastin plus chemotherapy helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin and chemotherapy alone, the Swiss drugmaker said.

This analysis showed that the combination helped people with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, having a median overall survival of 19.2 months, versus 14.7 months for the other group.

Roche also said that follow-up phase III data showed Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death.

Alecensa more than tripled median progression-free survival (34.8 months compared to 10.9 months for Pfizer's crizotinib), the group said.

Copyright (c) 2018 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.